Lv1
6 积分 2025-08-19 加入
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
1个月前
已完结
Exploring the next generation of antibody–drug conjugates
1个月前
已完结
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer
2个月前
已完结
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer
2个月前
已完结
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
3个月前
已完结
Evolution of low HER2 expression between early and advanced-stage breast cancer
3个月前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
3个月前
已完结
Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer
3个月前
已完结
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
3个月前
已完结
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
3个月前
已完结
皖公网安备34019202002308
